Should I Buy LFMD? LFMD 2026 Analysis

Should You Buy LifeMD Inc (LFMD) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

3.370

1 Day change

-0.88%

52 Week Range

15.840

Analysis Updated At

2026/01/26

LifeMD Inc (LFMD) is not a strong buy at the moment for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock is currently facing headwinds from competitive pressures, declining financial performance, and bearish technical indicators. While analysts maintain a Buy rating, the lowered price targets and lack of immediate growth catalysts suggest waiting for a clearer turnaround or stronger positive signals before investing.

Technical Analysis

The technical indicators for LFMD are bearish. The MACD is negatively expanding, RSI is neutral at 39.167, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 3.839, with key support at 3.47 and resistance at 4.208. Overall, the technical outlook suggests a weak trend with no immediate signs of recovery.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The low put-call ratios indicate a bullish sentiment in options trading. However, the implied volatility is high (96.97), suggesting significant uncertainty in the stock's future price movement.

Technical Summary

Sell

Buy

Positive Catalysts

Analysts expect growth to reaccelerate in 2026 due to partnerships with Eli Lilly and Novo, the launch of oral Wegovy, and Medicare obesity coverage.
Revenue increased by 12.95% YoY in Q3 2025, indicating some operational progress.

Neutral/Negative Catalysts

Increased competition from low-cost compounders is pressuring the weight management business.
Financial performance in Q3 2025 showed a decline in net income (-15.67% YoY) and EPS (-23.08% YoY).
Gross margin dropped by 3.20% YoY, reflecting operational challenges.
Analysts have significantly lowered price targets, citing competitive pressures and revised guidance.

Financial Performance

In Q3 2025, LifeMD's revenue grew by 12.95% YoY to $60.17 million. However, net income declined by 15.67% YoY to -$4.58 million, and EPS dropped by 23.08% YoY to -0.1. Gross margin also decreased by 3.20% YoY to 87.69%. Overall, the financial performance reflects growth in revenue but worsening profitability and operational efficiency.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts maintain a Buy rating but have significantly lowered price targets, with the highest being $10 (down from $18) and the lowest at $8. Analysts cite competitive pressures and revised guidance as reasons for the adjustments. However, they are optimistic about growth reacceleration in 2026 due to strategic partnerships and new product launches.

7 Analyst Rating

Wall Street analysts forecast LFMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LFMD is 9.67 USD with a low forecast of 6 USD and a high forecast of 15 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

1 Hold

0 Sell

Strong Buy

Current: 3.400

Low

Averages

9.67

High

Current: 3.400

Low

Averages

9.67

High

H.C. Wainwright

Yi Chen

Buy

downgrade

$13 -> $9

AI Analysis

2025-11-19

Reason

H.C. Wainwright

Yi Chen

Price Target

$13 -> $9

AI Analysis

2025-11-19

downgrade

Buy

Reason

H.C. Wainwright analyst Yi Chen lowered the firm's price target on LifeMD to $9 from $13 and keeps a Buy rating on the shares following a top- and bottom-line miss in Q3. LifeMD, which is now a pure-play telehealth and pharmacy platform after the company divested its majority ownership in WorkSimpli, updated its 2025 total revenue guidance and the firm adjusted its projections accordingly, the analyst noted.

KeyBanc

Scott Schoenhaus

Overweight

downgrade

$12 -> $8

2025-11-19

Reason

KeyBanc

Scott Schoenhaus

Price Target

$12 -> $8

2025-11-19

downgrade

Overweight

Reason

KeyBanc analyst Scott Schoenhaus lowered the firm's price target on LifeMD (LFMD) to $8 from $12 and keeps an Overweight rating on the shares. The firm notes LifeMD is being impacted by low-cost compounders despite the FDA outlawing the practice earlier this year. However, KeyBanc expects cash prices for brand-name GLP-1s to continue to come down as well as stricter enforcement against compounders in FY26, which should benefit LifeMD due to its partnerships with Eli Lilly (LLY) and Novo (NVO). The firm also expects the launch of oral Wegovy in early FY26 to drive higher weight management subscribers.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for LFMD

Unlock Now

LFMD Should I Buy

LFMD Should I Buy

Should You Buy LifeMD Inc (LFMD) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch